DigestRedComo funciona
Red
/
Empresas
Ag
No verificado

Agenus Inc.

Sobre qué escribimos

BiotecnologíaFarmacéuticaMedicina - VariosOncologíaSalud

90 Comunicados de prensa

Ver todos los comunicados de prensa
06/11/2026
Eventos
Industria
Higiene alimentaria
Farmacéutica
Oncología
Sanidad
Tercera edad
Biotecnología
Medicina - Varios
Ciencia
Ir de compras
Asistencia a la infancia
Salud
Agenus Reports More Than Half of Patients with Refractory MSS Metastatic Colorectal Cancer Achieved Long-Term Survival Following BOT+BAL Treatment at SITC 2026
Fuente
Agenus Inc.
Editor
Business Wire
1.00
0
05/11/2026
Mercado de valores
Oncología
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Agenus Reports Third Quarter 2026 Results, Highlighted by First Marketing Authorizations for BOT+BAL and Global Investigator Support for Phase 3 ROBBIN Study
Fuente
Agenus Inc.
Editor
Business Wire
1.00
0
02/11/2026
Web y redes sociales
Biotecnología
Farmacéutica
Salud
Oncología
Agenus to Participate in Rodman & Renshaw Virtual Fireside Chat
Fuente
Agenus Inc.
Editor
Business Wire
1.00
0
02/11/2026
Industria
Oncología
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Agenus Announces Nature Medicine Publication of Multicenter UNICORN Phase 2 Trial Demonstrating Deep Responses with Neoadjuvant BOT+BAL in Resectable Colon Cancer
Fuente
Agenus Inc.
Editor
Business Wire
1.00
0
25/10/2026
Oncología
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Eventos
Industria
Agenus Reports 72% of Patients with Locally Advanced dMMR Colon Cancer Had No Cancer Remaining at Surgery Following Six Weeks of BOT+BAL in Phase 2 NEOASIS Study at ESMO 2026
Fuente
Agenus Inc.
Editor
Business Wire
1.00
0
22/10/2026
Biotecnología
Salud
Farmacéutica
Medicina - Varios
Oncología
Finanzas
Mercado de valores
Agenus to Provide Third Quarter 2026 Financial Report and Development Update
Fuente
Agenus Inc.
Editor
Business Wire
1.00
0
09/10/2026
Eventos
Web y redes sociales
Biotecnología
Farmacéutica
Salud
Oncología
Agenus to Participate in Chardan’s 10th Annual Healthcare Investor Conference
Fuente
Agenus Inc.
Editor
Business Wire
1.00
0
08/10/2026
Eventos
Industria
Oncología
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Armenia Grants First Marketing Authorizations for Agenus’ BOT+BAL in Previously Treated MSS Metastatic Colorectal Cancer
Fuente
Agenus Inc.
Editor
Business Wire
1.00
0
03/10/2026
Biotecnología
Salud
Farmacéutica
Medicina - Varios
Oncología
Eventos
Industria
Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026
Fuente
Agenus Inc.
Editor
Business Wire
1.00
0
02/10/2026
Eventos
Industria
Biotecnología
Salud
Farmacéutica
Medicina - Varios
Oncología
Agenus to Present BOT+BAL Long-Term Survival Data and Translational Research With agenT-797 in Colorectal Cancer at SITC 2026
Fuente
Agenus Inc.
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0